Understanding the Influence of API Conformations on Amorphous Dispersion Formation Potential Predictions using the R3m Molecular Descriptor
DOI
10.1021/acs.molpharmaceut.3c00909
Document Type
Journal Article
Publication Date
2-5-2024
Publication Title
Molecular Pharmaceutics
Volume
21
Issue
2
First Page
770
Last Page
780
ISSN
15438384
Keywords
amorphous solid dispersions, molecular conformations, molecular descriptors, molecular dynamics, QSPR
Abstract
The R3m molecular descriptor (R-GETAWAY third-order autocorrelation index weighted by the atomic mass) has previously been shown to encode molecular attributes that appear to be physically and chemically relevant to grouping diverse active pharmaceutical ingredients (API) according to their potential to form persistent amorphous solid dispersions (ASDs) with polyvinylpyrrolidone-vinyl acetate copolymer (PVPVA). The initial R3m dispersibility model was built by using a single three-dimensional (3D) conformation for each drug molecule. Since molecules in the amorphous state will adopt a distribution of conformations, molecular dynamics simulations were performed to sample conformations that are probable in the amorphous form, which resulted in a distribution of R3m values for each API. Although different conformations displayed R3m values that differed by as much as 0.4, the median of each R3m distribution and the value predicted from the single 3D conformation were very similar for most structures studied. The variability in R3m resulting from the distribution of conformations was incorporated into a logistic regression model for the prediction of ASD formation in PVPVA, which resulted in a refinement of the classification boundary relative to the model that only incorporated a single conformation of each API.
Open Access
Hybrid_Gold
Repository Citation
DeBoyace, K., Bookwala, M., Zhou, D., Buckner, I., & Wildfong, P. (2024). Understanding the Influence of API Conformations on Amorphous Dispersion Formation Potential Predictions using the R3m Molecular Descriptor. Molecular Pharmaceutics, 21 (2), 770-780. https://doi.org/10.1021/acs.molpharmaceut.3c00909